🚀 VC round data is live in beta, check it out!
PharmaResearch Valuation Multiples
Discover revenue and EBITDA valuation multiples for PharmaResearch and similar public comparables like Jiuzhou Pharmaceutical, Sai Life Sciences, Piramal Pharma, Fagron and more.
PharmaResearch Overview
About PharmaResearch
PharmaResearch Co Ltd formerly Pharma Research Products Co Ltd is a bio pharmaceutical firm which realizes a new treatment paradigm for regenerative medicine. Its products include Rejuran, Rejuvenex, and Re-An eye drops. It also provides medical devices, cosme ceuticals, and dietary supplements.
Founded
2001
HQ
Employees
N/A
Website
Financials (LTM)
EV
$2B
PharmaResearch Financials
PharmaResearch reported last 12-month revenue of $394M and EBITDA of $167M.
In the same LTM period, PharmaResearch generated $301M in gross profit, $167M in EBITDA, and $125M in net income.
Revenue (LTM)
PharmaResearch P&L
In the most recent fiscal year, PharmaResearch reported revenue of $367M and EBITDA of $166M.
PharmaResearch expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $394M | XXX | $367M | XXX | XXX | XXX |
| Gross Profit | $301M | XXX | $280M | XXX | XXX | XXX |
| Gross Margin | 76% | XXX | 76% | XXX | XXX | XXX |
| EBITDA | $167M | XXX | $166M | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 45% | XXX | XXX | XXX |
| EBIT Margin | 40% | XXX | 40% | XXX | XXX | XXX |
| Net Profit | $125M | XXX | $115M | XXX | XXX | XXX |
| Net Margin | 32% | XXX | 31% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
PharmaResearch Stock Performance
PharmaResearch has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
PharmaResearch's stock price is $211.45.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $11.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialPharmaResearch Valuation Multiples
PharmaResearch trades at 4.5x EV/Revenue multiple, and 10.7x EV/EBITDA.
EV / Revenue (LTM)
PharmaResearch Financial Valuation Multiples
As of April 19, 2026, PharmaResearch has market cap of $2B and EV of $2B.
Equity research analysts estimate PharmaResearch's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
PharmaResearch has a P/E ratio of 17.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 4.5x | XXX | 4.9x | XXX | XXX | XXX |
| EV/EBITDA | 10.7x | XXX | 10.8x | XXX | XXX | XXX |
| EV/EBIT | 11.3x | XXX | 12.2x | XXX | XXX | XXX |
| EV/Gross Profit | 5.9x | XXX | 6.4x | XXX | XXX | XXX |
| P/E | 17.6x | XXX | 19.0x | XXX | XXX | XXX |
| EV/FCF | 16.3x | XXX | 17.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified PharmaResearch Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
PharmaResearch Margins & Growth Rates
PharmaResearch's revenue in the last 12 month grew by 24%.
PharmaResearch's rule of 40 is 67% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
PharmaResearch's rule of X is 105% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
PharmaResearch Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Margin | 42% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | 17% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 67% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 105% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 9% | XXX | 16% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 4% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 37% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
PharmaResearch Public Comps
See public comps and valuation multiples for other Contract Research & Manufacturing comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| PharmaResearch | XXX | XXX | XXX | XXX | XXX | XXX |
| Jiuzhou Pharmaceutical | XXX | XXX | XXX | XXX | XXX | XXX |
| Sai Life Sciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Piramal Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Fagron | XXX | XXX | XXX | XXX | XXX | XXX |
| ST Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
PharmaResearch M&A Activity
PharmaResearch acquired XXX companies to date.
Last acquisition by PharmaResearch was on XXXXXXXX, XXXXX. PharmaResearch acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by PharmaResearch
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialPharmaResearch Investment Activity
PharmaResearch invested in XXX companies to date.
PharmaResearch made its latest investment on XXXXXXXX, XXXXX. PharmaResearch invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by PharmaResearch
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout PharmaResearch
| When was PharmaResearch founded? | PharmaResearch was founded in 2001. |
| Where is PharmaResearch headquartered? | PharmaResearch is headquartered in South Korea. |
| Who is the CEO of PharmaResearch? | PharmaResearch's CEO is Ki-seok Kang. |
| Is PharmaResearch publicly listed? | Yes, PharmaResearch is a public company listed on Korea Exchange. |
| What is the stock symbol of PharmaResearch? | PharmaResearch trades under 214450 ticker. |
| When did PharmaResearch go public? | PharmaResearch went public in 2015. |
| Who are competitors of PharmaResearch? | PharmaResearch main competitors are Jiuzhou Pharmaceutical, Sai Life Sciences, Piramal Pharma, Fagron. |
| What is the current market cap of PharmaResearch? | PharmaResearch's current market cap is $2B. |
| What is the current revenue of PharmaResearch? | PharmaResearch's last 12 months revenue is $394M. |
| What is the current revenue growth of PharmaResearch? | PharmaResearch revenue growth (NTM/LTM) is 24%. |
| What is the current EV/Revenue multiple of PharmaResearch? | Current revenue multiple of PharmaResearch is 4.5x. |
| Is PharmaResearch profitable? | Yes, PharmaResearch is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of PharmaResearch? | PharmaResearch's last 12 months EBITDA is $167M. |
| What is PharmaResearch's EBITDA margin? | PharmaResearch's last 12 months EBITDA margin is 42%. |
| What is the current EV/EBITDA multiple of PharmaResearch? | Current EBITDA multiple of PharmaResearch is 10.7x. |
| What is the current FCF of PharmaResearch? | PharmaResearch's last 12 months FCF is $109M. |
| What is PharmaResearch's FCF margin? | PharmaResearch's last 12 months FCF margin is 28%. |
| What is the current EV/FCF multiple of PharmaResearch? | Current FCF multiple of PharmaResearch is 16.3x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.